This research section is the first of its kind in the United States. This innovative team uses technology to predict clinical endpoints, such as death, stroke, and heart attack, that are difficult to study in large trials. For example, we are using the latest magnetic resonance imaging (MRI) technology to follow cardiovascular disease progression in a completely painless and risk-free fashion.& Therefore, we can follow the progression or regression of atherosclerosis in the heart using imaging techniques that will enable to determine if a particular drug therapy is doing what is necessary to predict those clinical endpoints. Using this approach, much less expensive research can be performed in large groups of patients. Extensive funding for this research has been received from the biomedical industry and from Spain.
The trial section is being headed by Dr. Michael Farkouh who trained at Mayo Clinic and Mount Sinai. The imaging aspect of this research will be under the auspices of Valentin Fuster. This is the first department of its kind in the world.